Skip to main content
. 2013 Nov 27;1:37–41. doi: 10.1016/j.ijchv.2013.11.008

Table 3.

Clinical Outcomes at 9 months Follow-up.

N = 304
MACE,n,%, 16(5.3)
Cardiovascular death,n,% 3 (1)
TLR,%,n 12 (4)
Target vessel related MI,n,% 8 (2.6)
Target lesion thrombosis,n,% 0 (0)

MACE denotes major adverse cardiac events, TLR target lesion revascularization, MI myocardial infarction